Online games teaching children hygiene and antibiotic resistance: Evaluation of the e-Bug games  by Farrell, D. et al.
trac
2
t
m
s
(
c
c
u
T
o
g
a
i
d
2
A
s
t
l
J
R
L
1
S
2
d
c
c
e
b
i
s
A
P
t
s
r
c
b
1
P
a
1
t
m
t
t
r
r14th International Congress on Infectious Diseases (ICID) Abs
screened by PCR analysis with primers speciﬁc for 6 car-
bapenemase genes. Ampliﬁcation products were sequenced
to determine the gene present.
Results: Twelve of the 15 patients studied were hospi-
talizated at the ICU. The most frequent sites of isolation
were the respiratory tract (16) and the blood (11). With the
exception of colistin (0% resistance) there were no antibi-
otics with good activity against these isolates. Of the other
antibiotics tested, tigecycline showed the best activity with
an MIC90 value of 2 mg/L. The genotypic study revealed
that the same strain was responsible for all the infections.
All the isolates harboured the bla-OXA-51—like gene and the
6 of them chosen to sequence the gene were identical and
100% homologous with the bla-OXA-66 gene. PCR showed
that the insertion sequence ISAba1 was present upstream of
the oxacillinase gene in all the isolates.
Conclusion: a) Molecular typing revealed that the out-
break detected in our hospital was due to a single A.
baumannii clonal group. b) The epidemic strain of A. bau-
mannii produces an OXA-66-ISAba1 carbapenem-hydrolyzing
oxacillinase. c) Even though the outbreak was controlled,
and the number of isolates decreased signiﬁcantly, the clone
responsible of the outbreak persisted at the hospital during
the following year.
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Background: e-Bug is a EC-funded antibiotic, hygiene
teaching resource aiming to reinforces an awareness of
microbes, respiratory hygiene and prudent antibiotics use
among junior and senior school children across Europe. e-
Bug junior web games were developed for children age 9-12
years. The e-Bug junior game has a number of ‘‘levels’’
teaching the given set of learning outcomes (LOs). Player,
shrunken inside human body, interacts with good and bad
cartoon microbes (Fig 1) as well as antibiotics and viruses.
Teaching the LOs is implemented through interaction with
microbes (making yogurt (Fig 3), ﬁnishing course of antibi-
otics (Fig 2). Knowledge is tested seamlessly before and after
each level in a Game Show style similar to the game ‘‘Do you
want to be a Millionaire?’’
Methods: Evaluation was primarily conducted in the UK
and online demonstrating statistically signiﬁcant knowledge
gain of the learning outcomes. This was complemented
by focus groups and observational studies with 29 pupils
taking part (and fully completing the pre and post question-
naire) from three schools. Before playing the game, only 4
pupils ‘‘agreed’’ that fungi were microbes while after play-
ing 18. Smaller improvements were seen in other questions
including: ‘‘We use microbes to make things like bread and
yogurt’’ (11 correct before, 23 correct after) and ‘‘Soap can
be used to wash away bad bugs’’ (20 before vs 24 after)
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Results: The main evaluation took place in May — August
009. Each of the completed levels was evaluated for sta-
istical signiﬁcance of knowledge change of the LOs. As
any questions were correct before and after the game, the
tatistically signiﬁcant improved responses were measured
using McNemar’s test), for the following questions: ‘‘if you
annot see a microbe it is not there’’, ‘‘most coughs and
olds get better without medicine’’ and in particular ‘‘we
se good microbes to make things like bread and yogurt’’.
here was a trend towards improved knowledge however in
ther questions did not reach statistic signiﬁcance
Conclusion: The study demonstrated that computer
ames can teach children about hygiene and antibiotics in
n enjoyable way. Further study is needed to evaluate an
mpact on behaviour change
oi:10.1016/j.ijid.2010.02.1583
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Background: It has been suggested that after the intro-
uction of ertapenem into hospital use, the amount of other
arbapenems and the rate of resistance to other antimi-
robials decreases. We conducted a retrospective study to
valuate these outcomes.
Methods: We studied 48 months (two 24 month-periods)
efore (PRE) and after (POST) the introduction of ertapenem
n August 2004. Antibiotic use was determined using the
tandard deﬁned daily dose (DDD) per 1000 patient/days.
ntimicrobial susceptibility testing to Escherichia coli,
seudomonas aeruginosa, Klebsiella pneumoniae and Acine-
obater baumanii was performed with the Vitek automated
ystem. We used chi-square for trend to compare rates of
esistance and changes in antimicrobial use.
Results: In the PRE-period, we analyzed 4072 E.
oli, 677 P. aeruginosa, 571K. pneumoniae, and 67 A.
aumanii isolates; in the POST 4648, 884, 559, and
09, respectively; antibiotic consumption was as follows:
RE-period: meropenem 89.9 DDD/1000/patients/days,
ntipseudomonal cephalosporins 90.9, and ceftriaxone
95.65; POST period: 75.3, 103.58, and 184.77, respec-
ively. The rate of antimicrobial susceptibility was: E. coli, to
eropenem in PRE-period 99.6% and in POST-period 98.05%,
o ceftazidime 88.67% and 84.75% (p < 0.000), respectively;
o P. aeruginosa, meropenem 67.41% and 61.74% (p = 0.004),
espectively, ceftazidime 63.74% and 62.12% (p = 0.3388),
espectively, and piperacillin/tazobactam 69.17% and
7.21%(p = 0.15), respectively; K. pneumoniae, meropenem
00% and 98.7% (p < 0.05), respectively, and ceftazidime,
6.60% and 90.29% (p = 0.018); A. baumanii, meropenem
5.2% and 79.09% (p = 0.08), respectively, and ceftazidime
6.14% and 58.88% (p = 0.12), respectively.
